Journal of Stroke and Cerebrovascular Diseases

Introduction and objectives Hydrocephalus is a common complication of aneurysmal subarachnoid haemorrhage. This is one of several standard indications for the insertion of an external ventricular drain, but there are no standard guidelines for timing of extraventricular drain discontinuation in this population. Therefore, the study aims were to examine the 1) factors associated with extraventricular drain duration in aneurysmal subarachnoid haemorrhage and 2) association between extraventricular drain duration and clinical and resource-based outcomes. Methods In this single centre retrospective cohort study, data for adult patients treated in the ICU between 2015-2023 with aneurysmal subarachnoid haemorrhage and requiring an extraventricular drain were analysed. Data were extracted from both a prospective patient registry and the electronic medical record. Linear regression modelling was used to identify the factors associated with extraventricular drain duration. Measures used to examine the association between extraventricular drain duration, and the outcomes of interest included hazard ratio, relative risk, and mean differences as appropriate for a specific outcome. Results Of the participants (n=205), 68% (n = 140) were female, mean age was 60.7 (SD 13.3) years and 71% (n = 145) had a modified Fisher score of 4. Mean extraventricular drain duration was 15.3 (SD 8.6) days. The number of days mechanically ventilated and extraventricular drain challenge by clamp trial were associated with an increased duration of extraventricular drain treatment. Increased extraventricular drain duration was associated with an increased incidence of ventriculoperitoneal shunt insertion, and an increase in ICU and hospital length of stay when extraventricular drain duration exceeded 20 days. Conclusion The factors associated with an increased duration of extraventricular drain treatment were a longer duration of mechanical ventilation. The outcomes associated with an increased duration of extraventricular drain treatment were an increased incidence of ventriculoperitoneal shunt insertion, an increased incidence of ventriculitis when extraventricular drain duration exceeded 20 days, and an increase in ICU length of stay. These study findings may inform the conduct of a larger multi-centre study to examine the factors associated with duration of treatment with extraventricular drain, and outcomes associated with extraventricular drain duration.

Background: Stroke imposes substantial mortality and socioeconomic burden in India, particularly among younger adults. However, prospective evidence on the prognostic value of baseline clinical and radiomics features for mortality prediction remains limited. Objective: To assess mortality at 28, 90, 180, and 365 days after stroke; characterize survival patterns across stroke subtypes and vascular territories; and identify baseline demographic, clinical, and radiomics predictors of mortality. Methods: This prospective cohort study recruited consecutive patients with stroke admitted to a tertiary care hospital in Mangalore, India. Demographic, clinical, laboratory, and radiomics features were collected at admission, and mortality was assessed at 28, 90, 180, and 365 days. Kaplan Meier analysis was used to compare survival across stroke subtypes and vascular territories, while Cox proportional hazards regression was used to identify independent baseline predictors of mortality. Results: Among 63 confirmed stroke cases, 38 (60%) had ischemic stroke (IS) and 25 (40%) had haemorrhagic stroke (HS). Within the middle cerebral artery (MCA) territory, HS patients demonstrated better survival than IS patients due to a greater burden of adverse baseline characteristics such as previous stroke, atrial fibrillation, and higher lesion volume in the IS-MCA subgroup. The combined clinical-radiomics model demonstrated superior prognostic performance than individual models, with higher concordance indices and consistently lower Akaike Information Criterion values. In the combined model, stroke severity (aHR = 2.35, 3.0, 2.93, 2.41) and DWI texture heterogeneity of lesion (aHR = 2.35, 2.11, 2.24, 2.10) were the strongest predictors of mortality across all time points. The CT attenuation heterogeneity (aHR = 1.81, 28 days; 1.76, 90 days; 1.80, 180 days) of lesion and age (aHR = 1.48, 365 days) were also significant predictors. Conclusion: The radiomics features provide critical complementary information to clinical parameters for predicting 28-day mortality, unlike during mid- to long-term follow-up where their incremental contribution appears to be limited. Our results may have important implications in resource-constrained settings for supporting personalized post-stroke management and rehabilitation.

Background In Kenya, stroke is one of the top five causes of mortality, with a high rate of inpatient mortality. The American Heart Association (AHA) and American Stroke Association (ASA) translated scientific evidence into evidence-based clinical practice guidelines aimed at reducing inpatient mortality and improving the quality of care for stroke patients. Despite the proven benefits of the ASA stroke guidelines in improving stroke care, translation of the guidelines in various settings remains a key challenge. This study aimed to quantify the gap between evidence-based recommendations and current stroke care practices in a peri-urban referral facility in Kiambu, Kenya. The study was conducted at xxxxxxxxxx Hospital, a peri-urban referral facility in Kiambu County, Kenya. Methods: We reviewed records of stroke patients attending xxxxxxxxxxx from January 1, 2020, to December 31, 2023. The study evaluated acute stroke management practices and secondary prevention against the 2019 American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Acute Ischemic Stroke. Results: The median distance travelled by stroke patients to the facility was 47.8 kilometres; further, the median onset-to-presentation time was 24 hours. The study evaluated eight clinical practices against the ASA guidelines. The facility lacked a dedicated stroke unit. Remarkably, patients arriving within the therapeutic window for intravenous alteplase and thrombectomy did not receive these treatments. Secondary prevention measures, including discharge on an antiplatelet regimen, were moderately adhered to; among the 86 eligible ischemic stroke patients, 67 (77.9%) were correctly discharged on aspirin. Similarly, 84/123 (68.3%) of the patients were discharged on statin therapy. Conclusion: Evidence-based stroke care recommendations were minimally adhered to at this peri-urban referral facility in Kiambu, Kenya. Contribution: This study quantifies the gap between evidence-based stroke care recommendations and current clinical practice in a peri-urban referral facility in Kenya, providing context-specific evidence to inform quality improvement initiatives and guideline implementation efforts in similar resource-constrained settings.

Background/Aims: Pre-stroke depression has been shown to be associated with worse functional outcomes and depression after stroke. However, it is not currently well understood whether pre-stroke mood disorders (e.g., depression, anxiety, mood and psychotic disorders, substance use disorder) are associated with withdrawal of life-sustaining treatment (WOLST) after a severe stroke. Methods: This was a retrospective cohort study within the Tufts Vascular Neurology Registry of patients hospitalized with severe acute ischemic stroke (AIS, defined as NIHSS [≥]10) or severe nontraumatic intracerebral hemorrhage (ICH, defined as ICH score [≥]2) between 2018 and 2022. Multivariate logistic regression was performed to identify predictors of WOLST. Results: This study included 405 patients with severe stroke. Patients who opted for WOLST were more likely to be older, female, have AIS, and experience more severe strokes. In an adjusted analysis (basic demographics, stroke type), a pre-stroke mood disorder was associated with WOLST (OR 2.15, 95% CI 1.11-4.15). In models stratified by stroke type (AIS vs. ICH) and adjusted for stroke severity, WOLST was associated with age in both groups and with mood disorder in patients with ICH. The WOLST event rate was higher in the ICH group (19% vs 11%). Conclusion: Pre-stroke mood disorder was associated with increased rates of withdrawal of care after severe stroke in this patient population. Opportunities to actively treat depression may be useful to include in goals of care discussions to mitigate the potential impact of this factor in decision-making. Consistent with prior studies, we observed a higher proportion of WOLST in older, female, and ICH patients. Future studies regarding the quality and content of goals of care discussions may help elucidate the differing effects of pre-stroke mood disorders on WOLST by stroke type seen in this study.

Background: Dexmedetomidine (DEX) and midazolam (MDZ) are commonly used agents for conscious sedation in patients with acute ischemic stroke (AIS) treated with endovascular thrombectomy (EVT). While DEX offers superior sedation quality and potential neuroprotective effects, it is also associated with risk of hemodynamic instability. High-quality evidence directly comparing their impact on functional outcomes after EVT is lacking. This trial aims to determine whether conscious sedation with DEX, compared to MDZ, improves functional outcomes in patients with AIS due to anterior circulation large vessel occlusion (LVO) undergoing EVT. Methods: PEACE (Dexmedetomidine versus Midazolam for Conscious Sedation during Endovascular Stroke Thrombectomy) is a prospective, randomized, open label, blinded-endpoint, multicenter trial. Up to 810 patients with AIS due to LVO in the anterior circulation within 24 hours of last known well will be randomly assigned in a 1:1 ratio to receive either DEX or MDZ for conscious sedation during EVT across 30 centers in China. Results: The primary end point is the proportion of patients achieving a modified Rankin Scale (mRS) score 0-2 at 90 days, analyzed in the intention-to-treat population using a modified Poisson regression model, with results expressed as a risk ratio. Key secondary outcomes include the ordinal distribution of mRS scores at 90 days, and successful recanalization. Safety outcomes include symptomatic intracranial hemorrhage within 48 hours, and mortality at 90 days. Conclusion: The PEACE trial will provide definitive, high-level evidence on the comparative efficacy and safety of DEX versus MDZ for conscious sedation during EVT in patients with AIS due to LVO in the anterior circulation, with the goal of guiding clinical practice.

Background Endovascular treatment of unruptured intracranial aneurysms (UIAs) often requires dual antiplatelet therapy with aspirin and a P2Y12 inhibitor. Clopidogrel remains widely used, but variable bioactivation and high on-treatment platelet reactivity have prompted interest in alternatives such as prasugrel. We compared thromboembolic and hemorrhagic outcomes after clopidogrel versus prasugrel use in endovascular UIA treatment. Methods We queried the TriNetX Global Collaborative Network for adults with UIA who underwent endovascular treatment between 2016 and 2025 and received aspirin plus clopidogrel or prasugrel. Cohorts were matched 1:1 using propensity score matching based on demographics and comorbidities. Outcomes were assessed at 6 months and 1 year and reported as odds ratios (ORs) with 95% confidence intervals (CIs). Results Among 15,496 adults, 711 matched pairs were included. At 6 months, no significant differences were observed for in-stent thrombosis (OR 0.77, 95% CI 0.38?1.57; p=0.47), cerebral infarction (OR 1.04, 95% CI 0.75?1.46; p=0.80), cerebral hemorrhage (OR 1.07, 95% CI 0.80?1.44; p=0.65), or gastrointestinal hemorrhage (OR 0.84, 95% CI 0.43?1.64; p=0.61). Findings remained nonsignificant at 1 year. Conclusions In this propensity-matched TriNetX analysis, clopidogrel and prasugrel were not associated with significant differences in thromboembolic or hemorrhagic outcomes after endovascular UIA treatment. Prasugrel may be a reasonable alternative P2Y12 inhibitor in selected patients, including those with suspected or documented clopidogrel non-response.

Introduction: Cerebral ischemia induces a reduction in brain pH. GPR4, a proton-sensing G protein-coupled receptor is highly expressed in vascular endothelial cells. Pharmacological inhibition of GPR4 with NE52-QQ57 (NEQQ) reduces ischemia-induced blood-brain barrier (BBB) disruption and brain injury. To facilitate targeting GPR4 in vivo, it is important to better define the effect of NEQQ on post-ischemia signaling and the pharmacokinetics of NEQQ in vivo. Methods: We performed biochemical analysis following transient middle cerebral artery occlusion (tMCAO). We used Liquid Chromatography-Mass spectrometry (LC-MS/MS) to quantify the concentration of NEQQ in serum, brain, and peripheral tissues. Results: NEQQ administration decreased the phosphorylation of PKA substrates, PKC substrates, ERK1/2, and CREB. LC-MS/MS analysis detected NEQQ in both ipsilateral and contralateral hemisphere of the brain at 5 h and 24 h after reperfusion, demonstrating that NEQQ crosses the BBB. In peripheral tissues, NEQQ exhibited highest level in kidney and lowest in the heart. In sham controls, average serum concentrations were ~4 and 0.9 g/g at 5 and 24 h, respectively. Following tMCAO, ipsilateral brain exhibited higher levels as compared to the contralateral side at 5 h while the difference diminished at 24 h. Conclusions: NEQQ attenuated the ischemia-induced activation of multiple signaling pathways. NEQQ exhibited broad distribution in peripheral organs, and its brain level was sufficient for GPR4 inhibition at 24 h after injection. These findings support the use of NEQQ as a pharmacological inhibitor of GPR4-mediated signaling following ischemic stroke.

Background Implantable loop recorders (ILRs) provide continuous rhythm monitoring. Professional society guidelines and expert consensus statements recommend ILR use for patients with recurrent syncope and cryptogenic stroke, but recommendations are weaker for other indications. We assessed ILR use over time and concordance between indication and clinical guidance. Methods We conducted a retrospective cohort study using Epic Cosmos data from 1/1/2020-12/31/2025. Among active patients with at least one of 13 diagnoses potentially eligible for ILR placement, we identified ILR placements and classified them by concordance with professional society guidance: concordant, possibly, or non-addressed. Annual incidence was estimated overall and by indication. We also described the proportion of patients who received longer-term (>7 days) rhythm monitoring in the year prior to placement. Results Of 47,046,706 patients with diagnoses potentially eligible for ILR placement, 201,103 (0.4%) had an ILR placed. ILR placements increased from 3.08 ILRs per 100,000 patient-days in 2020 to 4.13 in 2025 (5.9% annual growth). The most common indications were cryptogenic stroke (28.6%) and atrial fibrillation without prior ablation (21.4%). Overall, 43.9% were guidance concordant, 28.5% possibly concordant, and 24.8% non-addressed. Relative annual growth in ILR placements per 100,000 patient-days was significant across all guidance categories: concordant (1.3%, 95% CI, 0.9%-1.7%), possibly concordant (5.5%, 95% CI, 5.0%-6.0%) and non-addressed (7.4%, 95% CI, 6.8%-8.0%). Among 125,631 outpatient placements, 50,181 (39.9%) had any prior long-term rhythm monitoring. Conclusion ILR placements are uncommon but increasing, with faster annual growth for indications that may not be guidance concordant. More than half of patients lacked long-term rhythm monitoring prior to outpatient ILR placement.

BackgroundMinor ischemic stroke is heterogeneous, and low NIHSS does not reliably identify patients at risk of deterioration or disability. We investigated whether integrating CT perfusion and angiographic vessel status identifies prognostically distinct phenotypes in a consecutive stroke-code cohort. MethodsWe analyzed consecutive adults with ischemic stroke, baseline NIHSS 0-5, prestroke modified Rankin Scale (mRS) [&le;]2, presentation within 24 hours of symptom onset or last known well, and emergency multiparametric CT. Patients were classified as no perfusion deficit/no vessel occlusion (PF-/VO-), perfusion deficit without visible occlusion (PF+/VO-), or perfusion deficit with vessel occlusion (PF+/VO+). The primary outcome was mRS [&ge;]3 at 90 days; early neurological deterioration (END), defined as an NIHSS increase [&ge;]2 points by 24 hours, was secondary. Multivariable logistic regression adjusted for prespecified covariates and additional variables associated with each outcome in univariable analysis. ResultsOf 2211 patients evaluated through the stroke-code pathway, 534 met inclusion criteria; 391 (73.2%) were PF-/VO-, 61 (11.4%) PF+/VO-, and 82 (15.4%) PF+/VO+. END occurred in 8.1% and mRS [&ge;]3 at 90 days in 17.6%. END occurred in 6.6%, 4.9%, and 17.1% of PF-/VO-, PF+/VO-, and PF+/VO+ patients, respectively (P=0.004), whereas mRS [&ge;]3 occurred in 13.3%, 34.4%, and 25.6%, respectively (P<0.001). Compared with PF-/VO-, PF+/VO+ was independently associated with END (adjusted odds ratio [aOR], 2.50 [95% CI, 1.03-6.06]), whereas PF+/VO- was independently associated with mRS [&ge;]3 at 90 days (aOR, 3.36 [95% CI, 1.67-6.73]). Findings were consistent across definitions of disabling versus nondisabling stroke and after exclusion of lacunar stroke. ConclusionsMultiparametric CT identified distinct risk phenotypes in minor ischemic stroke. Perfusion deficit without visible vessel occlusion was associated with 90-day disability, whereas combined perfusion deficit and vessel occlusion identified patients at increased risk of END. Tissue perfusion and vessel status may provide complementary information for acute risk stratification and future trial enrichment.

Abstract Background: Despite the high stroke burden in the elderly, their thrombolysis utilization is suboptimal partly due to heightened hemorrhagic risk. Observational data suggest that low-dose thrombolysis may offer comparable efficacy to standard-dose with a trend toward reduced symptomatic intracranial hemorrhage (sICH), yet high-level evidence for low-dose thrombolysis in this broad population remains absent. Objective: To evaluate the safety and efficacy of low-dose intravenous tenecteplase thrombolysis in elderly stroke patients within 4.5 hours of ischaemic stroke onset. Methods and design: The DATE-AGING trial is a multicenter, prospective, randomized, open-label, blinded-end point (PROBE) non-inferiority study. Eligible participants are elderly patients (aged [&ge;]70 years)with acute ischemic stroke who meet current guideline recommendations for intravenous thrombolysis within 4.5 hours of symptom onset will be randomly assigned to Low-dose Tenecteplase group (0.175 mg/kg, max 17.5 mg) or Standard-dose Tenecteplase group (0.25 mg/kg, max 25 mg). The primary outcome was excellent functional outcome, defined as a mRS 0-1 assessed at 90-day post-randomization. Safety outcomes included sICH within 36 hours and mortality at 90 days. Discussions: The DATE-AGING trial is intended to provide high-quality evidence for low-dose tenecteplase intravenous thrombolysis in elderly patients with acute ischemic stroke. Trial registry number: NCT07294209(https://clinicaltrials.gov/study/07294209). Keywords: elderly patients, acute ischemic stroke, intravenous thrombolysis, low-dose tenecteplase

Introduction Mechanical thrombectomy has been well-established as the standard of care treatment for patients with moderate to severe acute ischaemic stroke secondary to large vessel occlusion. However, the clinical value of endovascular treatment (EVT) in patients presenting with minor stroke and low baseline National Institutes of Health Stroke Scale scores remains incompletely defined, with limited high-quality clinical evidence. This protocol outlines the methodology of a randomized trial designed to evaluate whether EVT combined with best medical therapy (BMT) achieves superior functional outcomes relative to BMT alone among patients with minor stroke. Methods and analysis Eligible patients with acute minor anterior circulation ischaemic stroke and confirmed large vessel occlusion (n=264) will be randomized via a computer generated block randomization sequence to receive either EVT plus BMT (intervention arm) or BMT alone (control arm). The primary efficacy outcome is the proportion of participants achieving excellent functional recovery, defined as a modified Rankin Scale score of 0 or 1 at 90 days. Primary safety outcomes comprise symptomatic intracranial haemorrhage within 48 hours after randomization (classified according to Heidelberg criteria) and all cause mortality at 90 days. Participants will be considered eligible if they satisfy all of the following inclusion criteria: (1) enrolment within 24 hours of stroke symptom onset or time last known well; (2) baseline NIHSS score of 2 - 5 accompanied by at least one focal neurological deficit (including altered consciousness, facial palsy, limb weakness, aphasia or hemispatial neglect); (3) angiographically confirmed acute occlusion of the intracranial internal carotid artery, the M1 segment of the middle cerebral artery, or a dominant M2 branch; (4) a hypoperfusion volume (Tmax >6s) [&ge;] 50mL on computed tomography or magnetic resonance perfusion imaging. Both intention to treat and per protocol analyses will be undertaken, and potential sources of heterogeneity in treatment effect magnitude will be explored. Ethics and Dissemination This study was approved by the ethnic committee from the First Affiliated Hospital of Wannan Medical University (2023-IRB90). The findings of this study will be disseminated through publication in peer-reviewed journals. Registration URL:https://www.clinicaltrial.gov; Unique identifier: NCT06143488.

Stroke is a leading cause of mortality and disability in Uganda, with a prevalence of approximately 2.5% and a 25-30% 30-day mortality rate, exacerbated by limited access to predictive tools and advanced diagnostics. Machine learning (ML) offers potential for early stroke risk stratification, but its application in resource-constrained settings like Uganda requires tailored models and rigorous performance evaluation, as well as assessment of misclassification patterns. This study aimed to develop and internally validate an ML-based predictive model for stroke using clinical and socio-demographic characteristics among patients at Mulago National Referral Hospital (MNRH) and residents of Wakiso District, Uganda, identify key predictors and assess misclassification patterns to enhance targeted prevention. A retrospective case-control study utilized secondary data from 1,016 participants (254 stroke cases, 762 controls) across three prior studies conducted between 2006 and 2015. Eight ML algorithms were evaluated using 5-fold cross-validation, with performance metrics including accuracy, sensitivity, positive predictive value, F1-score, and area under receiver operator characteristics curve (AU-ROC). McNemars test compared model classification performance of the top 2 models. Feature importance identified key predictors, and misclassification patterns were analyzed using classification matrix and line graphs. The Random Forest (RF) model achieved the highest performance (95.18% accuracy, 90.10% F1-score, 97% AU-ROC). McNemars test confirmed RFs superior classification (p=0.01). Age, systolic blood pressure, total cholesterol, and waist-hip ratio were the top drivers of RF stroke predictions. RF misclassified 8.3% of stroke cases and 3.3% of non-stroke cases, due to overlaps in risk profiles (e.g., lower cholesterol, systolic blood pressure and age in false negatives). The RF model demonstrates strong potential for stroke risk prediction in Uganda, leveraging routine data to prioritize high-risk individuals. Misclassification analysis highlights areas for model refinement, supporting its potential for integration into clinical workflows for early intervention and stroke prevention in resource-limited settings. Future external validation across diverse populations is recommended.

Ogerin, a positive regulator of GPR68, reduces infarct volume and attenuates blood-brain barrier (BBB) leakage post transient middle cerebral artery occlusion (tMCAO). These data support the potential use of Ogerin for ischemic protection. For therapeutic interventions, tissue distribution, kinetics, and brain penetration are important characteristics for a compound. For these reasons, we performed liquid chromatography-mass spectrometry (LC-MS) analysis of Ogerin in mice. At 3 hours following intraperitoneal (IP) injection, liver exhibited highest level of Ogerin among all major organs assessed. We further analyzed time-dependent changes in Ogerin concentration in serum following intravenous delivery. Brain Ogerin level was ~140 ng/g at 2 hour and ~0.06ng/g at 24 hours. The brain-to-serum ratio of Ogerin was ~0.6 at 5 hr. To determine the effect of Ogerin on signaling, we collected samples 24 hours after tMCAO with or without Ogerin delivered and performed Western blotting. Consistent with the diminished level of Ogerin in brain at 24 hour, tMCAO increased similar changes in phosphorylation of PKA substrates and PKC substrates in vehicle- and Ogerin-treated groups. The pharmacokinetic data suggests that Ogerin is effective mainly during acute hours after injection. This finding generates important insights on the design of effective protocol for Ogerin delivery to potentiate GPR68 function in vivo.

Introduction: Hematoma expansion is a main cause of early worsening after spontaneous intracerebral hemorrhage (ICH). Many hospitals in low income countries have no invasive pressure monitoring and no automated pupillometer. Staff use the Glasgow Coma Scale (GCS) and a penlight to check the pupils, and pupil changes seen with a penlight usually come late. The speed of pupil constriction may change earlier, and smartphones record video fast enough to measure it. Methods and analysis: This will be a single-centre prospective cohort study of 120 adults with ICH on non-contrast computed tomography (NCCT) who arrive within 24 hours of symptom onset. At admission and every 6 hours until 48 hours, we will record a 6 second smartphone video of each eye reacting to a flash, using an eyecup that blocks ward light. Open-source software will measure the pupil diameter in every frame. The main measure is constriction velocity (CV). The primary outcome is hematoma expansion (an increase of more than 6 mL or more than 33%) on NCCT at 24 hours. Secondary outcomes are a fall of 2 or more GCS points within 48 hours and in-hospital death. The primary analysis estimates the area under the receiver operating characteristic curve for the percentage fall in CV from each patient's first recording. Ethics and dissemination: Patients or their legal representatives will give written consent. Results will be submitted to a peer-reviewed journal, and the analysis code will be made public.

Background Accurate prediction of 90-day outcomes following ischemic stroke is crucial for optimizing clinical strategies. This study aimed to systematically review and meta-analyze studies using deep learning (DL) and hand-crafted radiomics (HCR) models for predicting 90-day modified Rankin Scale (mRS) outcomes after ischemic stroke. Methods We followed the PRISMA guidelines for systematic reviews. Four databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched comprehensively for studies published up to September 2025. Inclusion criteria encompassed original research focusing on ischemic stroke patients with mRS at 90 days as the primary outcome and predictive models utilizing imaging biomarkers from CT or MRI. Quality assessment of the included studies was conducted using the PROBAST and and METhodological RadiomICs Score (METRICS) tools. Results Seventeen studies were included in the quantitative meta-analysis. Models demonstrated good prognostic performance for 90-day outcomes, with pooled AUCs of 0.85 (95% CI: 0.80-0.86) for internal and 0.74 (95% CI: 0.67-0.89) for external validation sets, with no significant difference (p=0.42). Deep learning and hand-crafted radiomics models showed comparable diagnostic accuracy in the primary analysis (p=0.667); a difference in sensitivity favouring hand-crafted radiomics emerged only in a post-hoc analysis after exclusion of one outlier study. Models incorporating clinical variables significantly outperformed imaging-only models (p<0.01). CT- and MRI-based models showed similar performance. Treatment-specific analyses revealed higher sensitivity for IVT-based models and higher specificity for combined MT+IVT models. Conclusions DL and HCR models demonstrate robust potential for predicting 90-day outcomes in ischemic stroke. Future research should focus on standardizing model evaluation metrics and incorporating explainable AI techniques to improve clinical applicability.

Background: Stroke survivors frequently experience post-stroke depression (PSD) and post-stroke anxiety (PSA), which may be underexamined by clinicians if patient mood status between discharge and follow-up is unknown. Digital monitoring may enable early identification of mood disturbances. Ecological momentary assessments (EMA) have been tested to capture mood fluctuations in patients regular environments, but no standardized procedure for monitoring PSA or PSD has been developed. Objective: Determine the feasibility and validity of EMA for evaluating subacute PSA and PSD in non-severe stroke patients. Methods: Patients with non-severe stroke discharged home responded to daily smartphone EMA questions concerning mood and activity for twelve weeks until follow-up. Questions based on symptoms of anxiety and depression were used to derive EMA Anx and EMA Dep indices, computed over five 15-day intervals. Convergent validity was assessed using follow-up Generalized Anxiety Disorder-7 (GAD-7) and Centre for Epidemiological Studies-Depression (CES-D) scores. Logistic regression models predicted PSA and PSD status at follow-up, with baseline models comprising stroke severity, age, sex, and mood status, to which EMA Anx or Dep were added. Results: Data from 118 patients were analyzed. EMA adherence was moderate, with 89 patients (75.4%) responding on 75 or more days. Correlations between EMA Anx and GAD-7 and between EMA Dep and CES-D generally strengthened at later intervals, with the average mood index generally showing the strongest associations. Adding EMA data from the third time interval (31-45 days) significantly improved model fit beyond the baseline models (Anxiety: {chi}-square = 7.08, p = 0.008, {delta}R-square = 0.060; Depression: {chi}-square = 28.0, p < 0.001, {delta}R-square = 0.256). Discussion: EMA is feasible in mild-to-moderate stroke patients and may facilitate early identification of post-stroke mood disturbances. Further analyses in more diverse populations are required to validate these findings.

Background: Low-density lipoprotein cholesterol (LDL-C) is an established risk factor for atherosclerotic cerebrovascular disease, but its effects on the cerebral microcirculation are poorly defined. We investigated whether LDL-C is associated with pericyte dysfunction in acute ischemic stroke (AIS) and explored underlying mechanisms. Methods: Serum soluble platelet-derived growth factor receptor-{beta} (sPDGFR{beta}) was measured in two independent AIS cohorts (n=97 and n=86). Cerebral pericyte transcriptional responses to LDL-C were analyzed by single-cell RNA sequencing in Apoe-knockout mice fed control or high-fat diet (n=4 [male/female: 2/2]/group), and cultured human brain pericytes were exposed to purified human LDL cholesterol with or without N-acetyl-L-cysteine. Results: Higher serum sPDGFR{beta} was associated with greater neurological deficit and circulating neurofilament light chain. LDL-C positively correlated with sPDGFR{beta} in both clinical cohorts. High-fat diet induced coordinated suppression of type-I interferon pathways, and a positive shift in reactive oxygen species-related transcriptional programs in mouse pericytes; exploratory sex-by-diet analyses suggested larger transcriptional responses in females. In cultured human pericytes, LDL-C induced oxidative-stress, lipid-handling, and ferroptosis-associated transcriptional programs while suppressing type-I interferon signaling. Cross-species enrichment analysis showed that LDL-C-induced and -repressed signatures in cultured pericytes aligned with the sex-by-diet interaction in Apoe-knockout mice. LDL-C also reduced cell-surface PDGFR{beta} and increased sPDGFR{beta} release in cultured pericytes, which were significantly attenuated by N-acetyl-L-cysteine, whereas LDH activity increased numerically but not significantly. Conclusions: Clinical and experimental findings support an LDL-pericyte axis linking atherogenic lipid stress to cerebral microvascular dysfunction, with possible sex-dependent modulation of oxidative stress and type-I interferon signaling as potential mechanisms.

Background: Excessive inflammation in early phases post-ischemic stroke is associated with poor long-term outcome and increased stroke recurrence. Interventions capable of downregulating persistent states of inflammation could improve recovery and prevent secondary stroke. Cardiovascular exercise (CE) has well-established anti-inflammatory effects but its capacity to attenuate the exaggerated inflammatory response triggered by ischemic stroke is unclear. Methods: We investigated the impact of eight weeks of CE on the serum concentration of inflammatory mediators in the early subacute phase post-stroke. Seventy-one patients with firstever ischemic stroke were randomly assigned to moderate-to-vigorous CE (n=45) or standard care (SC) (n=26). Concentrations of CRP, IL-6, IL-8, IL-10, TNF- and IL-1{beta} were measured at baseline and after the interventions. Differences between groups were analyzed with linear mixed models adjusted for age and sex. Results: Compared with the CE group, the SC group showed significant increases in IL-6 ({beta}=0.585, 95% CI=0.164-1.006, p=0.0073), IL-8 ({beta}=0.160, 95% CI=0.004-0.317, p=0.0447), and TNF- ({beta}=0.0845, 95% CI=0.0137-0.1553, p=0.0206). The SC group also showed greater increases in CRP ({beta}=0.250, 95% CI=-0.407, 0.906, p=0.4499) and IL-10 ({beta}=0.251, 95% CI=-0.024, 0.527, p=0.0729) but group differences were not significant. IL-1{beta} levels remained stable and differences between groups were not significant ({beta}=-0.008, 95% CI=-0.058, 0.042, p=0.7618). Conclusions: When introduced in the early subacute phase of stroke recovery, moderate-tovigorous CE mitigates increases in inflammation, but the effect differs across mediators. To what extent reducing the inflammatory response in the early stages post-stroke with CE can impact longterm recovery and stroke recurrence needs to be determined.

BACKGROUND: Existing models for discharge to long-term institutional care after stroke are developed within single health systems and pool to an area under the curve near 0.80, but none is accompanied by an estimate of how much of the outcome is a property of the health system rather than the patient. METHODS: Secondary analysis of the International Stroke Trial, a randomised trial in 19,435 patients with suspected acute ischaemic stroke recruited in 1991-1996 across 36 countries. Among 14,885 survivors to six months with residence recorded, we developed and internally validated a logistic prognostic model for residential or nursing-home residence using 17 admission-day terms, and compared it against a pre-specified benchmark of age and stroke syndrome alone. Between-country variation was estimated by a method-of-moments decomposition with a cluster bootstrap. RESULTS: Institutional residence was recorded for 1,984 of 14,885 survivors (13.3%); the model was fitted on 14,121 patients containing 1,935 events. In 10-fold cross-validation with the whole procedure refitted per fold, the out-of-fold c-statistic was 0.789, calibration slope 0.987, calibration-in-the-large 0.1371 predicted against 0.1370 observed, and Brier score 0.1013. A benchmark of age and stroke syndrome alone reached an optimism-corrected 0.774 against 0.790 for the full model, a corrected difference of 0.0160. Between-country variation gave an intraclass correlation of 0.0409 (0.0191 to 0.0673), and in leave-one-country-out validation the c-statistic ranged from 0.635 to 0.823 across the 14 countries with enough events to estimate it. CONCLUSIONS: Institutional residence after stroke can be stratified at admission with discrimination comparable to existing models and calibration that holds in unseen patients, but almost all of the signal is carried by age and stroke syndrome. Performance varies substantially between countries, pointing to placement systems as the limit on what a pooled model can do.

Background and Purpose: Neonatal hypoxia-ischemia (NHI) is a leading cause of mortality and long-term neurodevelopmental disability. Therapeutic hypothermia (TH) is currently the only established treatment for NHI; however, its efficacy remains limited, underscoring the need for adjunctive neuroprotective strategies. Lactate is now regarded as a major metabolic substrate of the brain and has previously been shown to exert neuroprotective effects following experimental NHI. We investigated whether lactate enhances hypothermia-induced neuroprotection and evaluated the optimal timing of administration and potential underlying mechanisms. Methods: Postnatal day 7 Wistar rats were subjected to NHI using the Rice-Vannucci model and treated with TH alone (2h at 32{degrees}C), sodium L-lactate alone, or combined L-lactate-TH. Animals underwent longitudinal magnetic resonance imaging (MRI) and behavioral assessments, complemented by histological, immunohistochemical, and Western blot analyses, including assessment of protein lactylation. The effect of sodium L-lactate administration timing relative to TH was also evaluated. Results: Lactate significantly enhanced the neuroprotective effects of TH, particularly when administered before hypothermia, resulting in greater lesion recovery, reduced neuroinflammation and apoptotic cell death, preserved neuronal integrity, and improved long-term motor and cognitive outcomes. Combined treatment preserved neuronal lactate transporter, prevented NHI-induced astrocytic glutamate transporter upregulation, modulated lactylation markers, supporting coordinated metabolic and epigenetic adaptations following NHI. Conclusions: Early lactate administration enhances the neuroprotective efficacy of TH following NHI. These findings identify lactate as a promising adjunct to TH and support its translational potential as a metabolic strategy to improve outcomes following NHI brain injury.